Barclay’s Alexander Kleban downgraded Smith & Nephew plc (ADR) SNN from Overweight to Equal-Weight while increasing the company’s price target by 0.81 percent.
Although the analyst believed the company’s transition to a higher growth platform is “underappreciated” by the general market in conjunction with remaining potential upside from M&A, results continue to disappoint.
"Additionally, emerging market headwinds should start to dissipate somewhere in H2 and Wound Devices are set for a late 2016-17 product cycle (Renasys re-launch),” stated Kleban.
Weak Management
Kleban viewed the upcoming management team transition as an initiative which wouldn’t take advantage of Smith and Nephew’s optionality as much as before. The analyst believed the management team would delay building S&N’s upper and lower extremities of its portfolio in recon in addition to delaying cost cutting initiatives.
Initiatives required to push S&N forward such as pruning assets with limited overlap was also expected to have a delay according to Kleban.
At time of writing, Smith and Nephew traded at $33.33, down 0.86 percent Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.